3/15/2021 8:02:26 AM
INOVIO Names Michael Cordera As EVP & General Counsel
2/24/2021 1:50:32 AM
INOVIO, QIAGEN Collaborate To Develop Next Generation Sequencing Companion Diagnostic For INOVIO's VGX-3100
2/23/2021 8:04:09 AM
INOVIO Reports First Dose In Phase 1B Clinical Trial For DNA Vaccine Against Lassa Fever, INO-4500, In West Africa
1/20/2021 4:38:50 PM
INOVIO Announces Proposed Public Offering Of Common Stock
1/6/2021 8:02:24 AM
INOVIO Announces Positive Efficacy Results For An Open-label Phase 2 Trial Of VGX-3100
1/4/2021 8:06:54 AM
INOVIO And Advaccine Enter Collaboration And License Agreement For COVID-19 DNA Vaccine Candidate INO-4800
12/24/2020 9:20:21 AM
INOVIO : Phase 1 Data Shows COVID-19 DNA Vaccine Candidate INO-4800 Immunogenic In All Vaccinated Subjects
12/15/2020 8:03:29 AM
INOVIO To Develop DMAb Candidates To Treat COVID-19 With Funding From DARPA And DoD JPEO-CBRND
12/10/2020 8:02:11 AM
INOVIO, Advaccine Report First Dosing Of Subject In Phase 2 Trial For COVID-19 DNA Vaccine Candidate INO-4800 In China